Timothy Fenn
Vice President at Lexeo Therapeutics
Greenwich, Connecticut, United States
Summary
👤
Senior🎓
Top SchoolTimothy Fenn is a CMC and analytical development leader with 13 years of experience translating complex biologics and gene therapy programs into robust manufacturing and release strategies. Currently Vice President at Lexeo Therapeutics after progressing through senior analytical roles, he has led Sf9 AAV manufacturing strategy, potency and viral titer assay development, and end-to-end CMC decision-making to support IND-enabling work. His background spans big pharma discovery and hands-on biophysical assay development at Merck and Boehringer Ingelheim, giving him deep expertise in assay design, method transfer to CROs/CMOs, and cost-of-goods justification. Trained as a structural biochemist (PhD, Brandeis), he brings an uncommon blend of rigorous protein science and practical program leadership that accelerates translational timelines.
13 years of coding experience
20 years of employment as a software developer
B.S. Molecular and Cellular Biology, B.S. Molecular and Cellular Biology at University of ConnecticutPh.D. Biochemistry, Ph.D. Biochemistry at Brandeis University
Github Skills (5)
biophysics9
computational-biology9
thermodynamics8
bioinformatics8
molecular-simulation7
Programming languages (1)
Github contributions (1)
mjschnie/ffx
Aug 2012 - Feb 2017
Force Field X - Software for Molecular Biophysics
Contributions:6 commits, 1 push in 4 years 7 months
molecularthermodynamicsbioinformaticsfieldforce-field
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.